IndiPHARM (Individualized Pharmacology)

The Advanced Research Projects Agency for Health (ARPA-H) has awarded Gary Miller, PhD, Vice Dean for Research Strategy and Innovation and Professor of Environmental Health Sciences, at Columbia University Mailman School of Public Health to led the Individual metabolome and exposome assessment for Pharmaceutical optimization (IndiPHARM).

IndiPHARM is a multicenter research initiative working to  revolutionize pharmacology by delivering a high-resolution precision monitoring system that can be used in large populations to assess drug efficacy and in individuals to tailor optimal drug treatment.  IndiPHARM is developing tools for personalized treatment by analyzing drug interactions with environmental exposures, along with a platform to measure hundreds of drugs and their metabolites and thousands of chemicals derived from the environment, diet, and lifestyles.

Ultimately, IndiPHARM aims to help pharmaceutical suppliers, insurance payors, and providers to anticipate and reduce adverse therapeutic effects, including side effects and inefficiencies, in both individuals and populations along with providing individuals and their doctors with a tool that can answer the question, “Is the drug or combination of drugs I am taking optimized for me?”

The IndiPHARM team includes investigators from the Mayo Clinic, Harvard Medical School, Emory University, Brown University, and the Jackson Laboratory.